The effect of elinogrel on high platelet reactivity during dual antiplatelet therapy and the relation to cyp 2c192 genotype: First experience in patients

P. A. Gurbel, K. P. Bliden, M. J. Antonino, G. Stephens, D. D. Gretler, M. M. Jurek, R. E. Pakyz, A. R. Shuldiner, P. B. Conley, U. S. Tantry

Research output: Contribution to journalArticle

Abstract

To study the effect of a new direct acting reversible P2Y12 inhibitor, elinogrel (PRT060128), and the relation to cytochrome P450 (CYP) polymorphisms in patients with high platelet reactivity (HPR) on standard dual antiplatelet therapy. Methods and Results: We studied the pharmacodynamic and pharmacokinetic effects of a single 60-mg oral dose of elinogrel in 20 of 45 previously stented stable patients with HPR. We also genotyped for CYP2C19*2,3,5,17 and CYP3A5*3. Platelet reactivity fell within 4 h of dosing, the earliest time point evaluated as measured by the following assays: maximum 5 and 10 μ. m ADP LTA (P < 0.001 for both vs. predosing); maximum 20 μ. m ADP LTA (P < 0.05); VerifyNow (P < 0.001); thrombelastography (P < 0.05); VASP phosphorylation (P < 0.01); and perfusion chamber assay (P < 0.05); this was reversible within 24 h in these same assays (P = ns vs. predosing for all assays). CYP2C19*2 was present in 44% of all patients but was more frequent in HPR patients (77% vs. 16%, P = 0.0004). Conclusions: HPR is reversibly overcome by a single 60-mg oral dose of elinogrel, a drug now being investigated in a phase 2 trial. CYP2C19*2 was associated with HPR during conventional dual antiplatelet therapy.

Original languageEnglish (US)
Pages (from-to)43-53
Number of pages11
JournalJournal of Thrombosis and Haemostasis
Volume8
Issue number1
DOIs
StatePublished - Jan 1 2010

    Fingerprint

Keywords

  • Clopidogrel
  • Elinogrel
  • P2Y12 receptor
  • Platelet inhibitor

ASJC Scopus subject areas

  • Hematology

Cite this

Gurbel, P. A., Bliden, K. P., Antonino, M. J., Stephens, G., Gretler, D. D., Jurek, M. M., Pakyz, R. E., Shuldiner, A. R., Conley, P. B., & Tantry, U. S. (2010). The effect of elinogrel on high platelet reactivity during dual antiplatelet therapy and the relation to cyp 2c192 genotype: First experience in patients. Journal of Thrombosis and Haemostasis, 8(1), 43-53. https://doi.org/10.1111/j.1538-7836.2009.03648.x